Infant Bacterial Therapeutics AB (IBT-B.ST)

Executive Summary

Infant Bacterial Therapeutics AB (IBT) is a Swedish biotech company pioneering live biotherapeutic products for severe neonatal conditions. Its lead candidate, IBP-9414 (Lactobacillus reuteri), is in late-stage development for preventing necrotizing enterocolitis (NEC) and feeding intolerance in very low birth weight preterm infants. NEC is a devastating disease with high mortality and no approved pharmacotherapy, representing a significant unmet medical need. IBP-9414's novel mechanism as a live biotherapeutic offers a differentiated approach, potentially modulating the infant gut microbiome to reduce inflammation and improve feeding tolerance. IBT has completed enrollment in its pivotal Phase 3 trial (The Connection Study) evaluating IBP-9414 for NEC prevention. Top-line data are expected in the second half of 2026, which could be a major value inflection point. The company is well-funded through this readout, with a focused pipeline and experienced leadership. Success would position IBT as a first-mover in neonatal biotherapeutics, targeting a multi-billion-dollar market. However, risks include regulatory hurdles, manufacturing complexity for live biotherapeutics, and trial execution. Overall, IBT represents a high-risk, high-reward opportunity with a clear catalyst timeline.

Upcoming Catalysts (preview)

• H2 2026Phase 3 Top-Line Data for IBP-941460% success
• 2027Regulatory Filing Submission (EMA/FDA)50% success
• 2026Potential Partnership or Licensing Deal40% success